View in EDS HTML Full Text PDF Full Text

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.

Saved in:
Bibliographic Details
Title: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.
Authors: Lin, Jing1,2 (AUTHOR), Guo, Qiaojuan2,3,4 (AUTHOR), Guo, Zengqing1,2,4 (AUTHOR), Lu, Tianzhu3 (AUTHOR), Chen, Gang2,5 (AUTHOR), Lin, Shaojun3 (AUTHOR), Chen, Mei3 (AUTHOR), Chen, Chuanben2,3 (AUTHOR), Lu, Jianping5 (AUTHOR), Zong, Jingfeng2,3 (AUTHOR), Tang, Lina6 (AUTHOR), Chen, Yu1,2,4,7 (AUTHOR) 13859089836@139.com, Pan, Jianji2,3 (AUTHOR) panjianji@126.com
Source: Radiation Oncology. 7/5/2022, Vol. 17 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:1748717X
DOI:10.1186/s13014-022-02073-8